Sandoz launches the 1st version of multiple sclerosis drugs in US

Sandoz

Sandoz launches the 1st version of multiple sclerosis drugs in US

Novartis International AG/ Sandoz reports US launch of Glatopa(TM), the first generic contender to Copaxone(R) 20mg. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is only in charge of the content of this declaration.

Glatopa is the first FDA-approved, substitutable generic version of Copaxone(R) 20mg – a treatment for relapsing forms of multiple sclerosis.

Sandoz has started shipping to US clients taking after recent FDA approval. Novartis and Sandoz, together are driving access to a full range of differentiated, high-quality MS therapeutic choices, supplemented by a full range of support services.

Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis organization, today announced the US launch of Glatopa(TM), the first generic version of TEVA’s Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-day by day multiple sclerosis treatment.

Peter Goldschmidt, President of Sandoz US said that Sandoz, together with Momenta, is glad to declare the US market launch of a completely substitutable generic version of multiple sclerosis drugs, after taking FDA’s approval.

MS is a debilitating disease affecting about a large portion of a million people in the US alone; just 50 per cent of those diagnosed are presently treated.

Glatopa, grew in a joint effort with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including the individuals who have encountered a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

The Sandoz service offering will incorporate financial backers to qualified patients, personalized injection training and 24-hour access to nurses for non-clinical inquiries.

Battling MS, together with different CNS disorders, is integral to the Novartis mission, and Sandoz’s Glatopa joins a wide MS portfolio including two approved therapies and one late-arrange development compound.

Copaxone(R) 20mg is TEVA’s top seller by far, generating $ 4.1 billion sales in the past four quarters. TEVA is declines by 1 per cent after hours on light volume, where as MNTA is up 3 per cent on increased volume.

Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

Some Microsoft employees stayed at data centers during Pandemic to keep all systems going

Some Microsoft employees stayed at data centers during Pandemic to keep all systems going

The Covid-19 pandemic ravaging the world for more than a year has forced companies and organizations to find viable solutions to keep the business going. Most found a solution in w
2 days ago
Meme stocks frenzy and 3 companies to follow

Meme stocks frenzy and 3 companies to follow

The doom and gloom about the stock market that has been predicted since the pandemic started has abated somewhat with the resilience shown by investors (helped by low-interest rate
2 days ago
US Space Force allows repurposed SpaceX rocket to launch GPS satellite

US Space Force allows repurposed SpaceX rocket to launch GPS satellite

A GPS navigation satellite built by Lockheed Martin is set to ride a reused SpaceX booster on a launch from Cape Canaveral, Florida, Thursday. It will be the first time a military
2 days ago
Disney boss says 40 pc ad revenue went to streaming sites, no plans of ad supported Disney+

Disney boss says 40 pc ad revenue went to streaming sites, no plans of ad supported Disney+

Walt Disney CEO Bob Chapel says the company’s advertising revenue for the upcoming fall television season was strong and went up by “double-digits” compared to 2019.
4 days ago
BlackRock ETFs breach $3 trillion mark in May

BlackRock ETFs breach $3 trillion mark in May

BlackRocks’ exchange-traded fund crossed $3 trillion for the first time in May, in sync with the ETF industry’s race to an all-time high of $9 trillion.
4 days ago
Flagship Pioneering, investor in Moderna raises $3.4 billion funds

Flagship Pioneering, investor in Moderna raises $3.4 billion funds

Flagship Pioneering, the bioplatform company, and the venture capital investor in Moderna, today announced that it had raised additional funding of $2.23 billion, which brings its
5 days ago